CA2949163A1 - Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof - Google Patents

Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof Download PDF

Info

Publication number
CA2949163A1
CA2949163A1 CA2949163A CA2949163A CA2949163A1 CA 2949163 A1 CA2949163 A1 CA 2949163A1 CA 2949163 A CA2949163 A CA 2949163A CA 2949163 A CA2949163 A CA 2949163A CA 2949163 A1 CA2949163 A1 CA 2949163A1
Authority
CA
Canada
Prior art keywords
aryl
heteroaryl
alkyl
cycloalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2949163A
Other languages
English (en)
French (fr)
Inventor
Xuedong Liu
Gan Zhang
Daniel Chuen-Fong Chan
Anthony D. Piscopio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of CA2949163A1 publication Critical patent/CA2949163A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2949163A 2014-05-14 2015-05-14 Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof Abandoned CA2949163A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461996702P 2014-05-14 2014-05-14
US201461996691P 2014-05-14 2014-05-14
US61/996,691 2014-05-14
US61/996,702 2014-05-14
PCT/US2015/030842 WO2015175813A1 (en) 2014-05-14 2015-05-14 Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2949163A1 true CA2949163A1 (en) 2015-11-19

Family

ID=54480695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2949163A Abandoned CA2949163A1 (en) 2014-05-14 2015-05-14 Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

Country Status (11)

Country Link
US (3) US9840520B2 (https=)
EP (1) EP3142652B1 (https=)
JP (1) JP6803235B2 (https=)
KR (1) KR20170003688A (https=)
CN (1) CN106456580B (https=)
BR (1) BR112016026518A2 (https=)
CA (1) CA2949163A1 (https=)
MX (1) MX2016014911A (https=)
RU (1) RU2016148863A (https=)
TW (1) TW201625620A (https=)
WO (1) WO2015175813A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524968B2 (en) 2017-10-18 2022-12-13 Hk Inno.N Corporation Heterocyclic compound as a protein kinase inhibitor
US12180185B2 (en) 2018-11-15 2024-12-31 Hk Inno.N Corporation Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP6803235B2 (ja) 2014-05-14 2020-12-23 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法
EP3233860B1 (en) * 2014-12-15 2020-01-29 Univerzita Palackého V Olomouci Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress
CN107613769A (zh) * 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
CN109843858B (zh) 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
MA46620A (fr) * 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
CN107513064B (zh) * 2017-09-27 2019-07-09 南昌大学 一种嘌呤异羟肟酸衍生物及其制备方法和应用
KR102847312B1 (ko) * 2021-12-30 2025-08-19 한국화학연구원 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
JP7807025B2 (ja) * 2021-12-30 2026-01-27 コリア リサーチ インスティチュート オブ ケミカル テクノロジー ピラゾロピリミジン誘導体及びこれを有効成分として含有する抗癌用薬学的組成物
CN114685507B (zh) * 2022-04-06 2024-01-12 山东大学 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用
KR102792443B1 (ko) * 2022-05-13 2025-04-08 서울대학교산학협력단 Cdk를 저해하는 신규 피롤로피리미디논 카복사미드 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암 치료용 약학적 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380258B2 (en) 1997-03-04 2002-04-30 G. D. Searle, L.L.C. Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
EP1042290A1 (en) * 1997-11-14 2000-10-11 G.D. SEARLE & CO. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20020049237A1 (en) 1998-03-17 2002-04-25 Newton Roger Schofield Statin-MMP inhibitor combinations
US6642255B2 (en) 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003900608A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
SI1611088T1 (sl) * 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
EP1648867B1 (en) 2003-07-17 2013-09-04 Plexxikon Inc. Ppar active compounds
US7834011B2 (en) * 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
US20100298557A1 (en) * 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
KR101168801B1 (ko) * 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
TWI600638B (zh) * 2010-01-22 2017-10-01 艾斯特隆製藥公司 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
WO2011146591A1 (en) * 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012170827A2 (en) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2013041407A1 (en) * 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
KR20140118575A (ko) * 2013-03-29 2014-10-08 한미약품 주식회사 신규한 하이드록사메이트 유도체
JP6803235B2 (ja) 2014-05-14 2020-12-23 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524968B2 (en) 2017-10-18 2022-12-13 Hk Inno.N Corporation Heterocyclic compound as a protein kinase inhibitor
US12180185B2 (en) 2018-11-15 2024-12-31 Hk Inno.N Corporation Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof

Also Published As

Publication number Publication date
JP2017515848A (ja) 2017-06-15
US10508122B2 (en) 2019-12-17
CN106456580A (zh) 2017-02-22
BR112016026518A2 (pt) 2017-08-15
RU2016148863A3 (https=) 2018-12-17
RU2016148863A (ru) 2018-06-18
WO2015175813A1 (en) 2015-11-19
US20170081343A1 (en) 2017-03-23
USRE47690E1 (en) 2019-11-05
MX2016014911A (es) 2017-04-06
CN106456580B (zh) 2020-09-04
EP3142652B1 (en) 2021-08-25
US20180044352A1 (en) 2018-02-15
US9840520B2 (en) 2017-12-12
JP6803235B2 (ja) 2020-12-23
KR20170003688A (ko) 2017-01-09
EP3142652A4 (en) 2017-11-29
EP3142652A1 (en) 2017-03-22
TW201625620A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
CA2949163A1 (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
AU2017258187B2 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
US10696670B2 (en) Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
CN108314677B (zh) 一种ezh2抑制剂及其用途
JP5931926B2 (ja) 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体
KR100830859B1 (ko) 이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
US10604514B2 (en) 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
JP2016503408A (ja) キナーゼ阻害剤としての置換三環式ベンゾイミダゾール
CA2903107C (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
US20240409528A1 (en) Binders of cereblon and methods of use thereof
US20240166693A1 (en) Methods and compounds for modulating myotonic dystropy 1
CN114007652A (zh) 小分子靶向溴/乙酰蛋白及其用途
AU2021355480B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
JP2019502663A (ja) （ｒ）−１−（４−（６−（２−（４−（３，３−ジフルオロシクロブトキシ）−６−メチルピリジン−２−イル）アセトアミド）ピリダジン−３−イル）−２−フルオロブチル）−ｎ−メチル−１ｈ−１，２，３−トリアゾール−４−カルボキサミドの塩形態および多形体
JP2022526979A (ja) Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
HK1229722B (zh) 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法
WO2026011129A1 (en) Azaindole rock inhibitors for the treatment of medical disorders
HK1229722A1 (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
HK1260678A1 (en) Salt forms and polymorphs of n-methyl-1h-1,2,3-triazole-4-carboxamide compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200519

FZDE Discontinued

Effective date: 20231116